'Biology and cancer research have developed together. Invariably, at each stage, the characteristics of the cancer cell have been ascribed to some defect in whatever branch of biology happens at the time to be fashionable and exciting; today, it is molecular genetics'. Tremendous transformations have occurred in cancer research since these few lines were written by John Cairns: the discovery of oncogenes and anti-oncogenes, and the successful development of 'magic bullets' targeting the proteins encoded by these oncogenes. Nevertheless, Cairns' message is still valid. In 1978, he observed the first attempts to apply the tools and concepts of molecular biology to cancer; today, this research field reflects multiple and diverse efforts that go 'beyond' molecular biology by looking for explanations that have been left aside during its development, or by privileging new approaches, fully original or actively pursued in other fields of biological research. Because of this specific characteristic of cancer research, it is possible to use it as an indicator of trends in biological research in general.
Introduction
Research on cancer recently underlined the limits of the molecular approach both at the theoretical and practical levels. Long gone is the time, when Weinberg (1982) could proudly announce that there are 'fewer and fewer oncogenes', the 'outlines of order and symmetry are emerging' and 'the oncogenes of the animal genome will be boiled down to a very small number of distinct types'. The number of oncogenes and tumour suppressor genes is permanently increasing, and each tumour is a unique patchwork of such mutations. The possibility of organizing these mutations into 'hallmarks of cancer' (Hanahan and Weinberg, 2000) or of distinguishing 'driver' and 'passenger' mutations (Greenman et al., 2007) does not fully alleviate the problem. On the practical side, it has to be admitted that despite this huge increase in knowledge, the rate of mortality has changed very little (Kiberstis and Travis, 2006) . And the use of the magic bullets derived from molecular knowledge is more difficult than previously imagined because rapid appearance of resistance; there are beneficial effects of these new therapies, but limited to a subset of patients. The ras oncogene, the twenty-fifth anniversary of whose discovery was recently celebrated (Downward, 2006) , is a wonderful example of these difficulties. Despite 30 000 publications on it, and treasures of imagination, the therapeutic value of its inhibition is still uncertain. In contrast, inhibition of general cellular activity such as the proteasome in the proteolytic pathway (Borczuk et al., 2007) , or some chaperone functions (Kamal et al., 2003) , can selectively inhibit the growth of tumours, with far fewer side effects than expected.
These difficulties not only boosted development of the new postgenomic technologies in cancer research, but also favoured new approaches, original or imported from other biological disciplines. This paper will characterize these new paths of research in cancer, and emphasize those that are also of interest for other fields of biology.
Reminiscences
New pathways are explored, corresponding to the description of new phenomena, both to understand the development of cancer and to find new weapons against it: such is the case, for instance, of attempts to determine the role of autophagy (Marx, 2006) and senescence (Bartkova et al., 2006) in tumour formation. But some of these apparently emerging approaches are not new at all, but rather revivals of past ideas and models that had their day but were abandoned in favour of the oncogene/tumour suppressor model. An example is the hypothesis that the alteration of the chromosome and the instability of the genome are the prime movers in oncogenesis. This hypothesis was supported by Theodor Boveri at the beginning of the twentieth century (Manchester, 1995) , and although not totally excluded from the present models, it was considered valid for a limited set of cancers. Genomic instability in most cases is considered as a consequence of the development of a tumour, not as the initial trigger of cancer. We will return to this distinction later. The debate has recently been reopened (Weaver and Cleveland, 2006) . Similarly, the metabolic alteration of cancer cells, in particular the activation of glycolysis, was considered by Warburg (1956) already in the 1920s as the origin of this transformation. This metabolic alteration has largely been ignored over the last two decades, but is now finding new experimental support (Ramanathan et al., 2005) , with molecular mechanisms linking this alteration to the activation of oncogenes. In both cases, the hypothesis had never been conclusively dismissed, and it lingered for decades in a kind of limbo, ready to spring forth again as soon as new observations were made, or mechanisms likely to link it with the present models of cancer were defined.
Epigenetic origin of cancer
The hypothesis that some variations in gene expression observed during oncogenesis, mostly the inactivation of tumour suppressor genes, could result from epigenetic variations, by DNA methylation and chromatin modification, has received increasing experimental support in recent years (Feinberg and Tycko, 2004; Lund and van Lohuizen, 2004) . Precise mechanisms linking epigenetic variations and somatic mutations have been proposed in simple models (Ferres-Marco et al., 2006) . More interestingly, it is easy to imagine how an epigenetic variation might pave the way to a somatic mutation, providing experimental support of the model of genetic assimilation initially proposed by Waddington (1941) 60 years ago.
The introduction of epigenetics into explanations of cancer is closely linked to two other bold hypotheses, which also recently received some experimental support. The first is that tumorigenic power is associated with a subfraction of the cells found in a tumour, so-called cancer stem cells (Marx, 2003) . This has been demonstrated in some forms of leukaemia, brain tumours (Bao et al., 2006) and colon cancer (O'Brien et al., 2007; Ricci-Vitiani et al., 2007) , and is suspected to be true for other tumours. The second hypothesis (Marx, 2003; Valk-Lingbeek et al., 2004) , which has less support at the moment, is that these cancer stem cells could be derived from somatic stem cells. Since these cells do not bear mutations, but have distinct properties owing to epigenetic variations, the presence of epigenetic variations in cancer would be a sign of their stem cell origin.
The idea that cancerous cells are undifferentiated or dedifferentiated cells is not new. In the nineteenth century, Julius Cohnheim considered that tumours originated from cells left during the development of the organism (Triolo, 1965) . In the 1960s, it was observed that many tumours reexpressed genes active during early embryogenesis, thus suggesting that cancer was a form of dedifferentiation. The role of the first discovered oncogenes in differentiation and development was eagerly looked for in the 1970s, without much success (Morange, 1997) . It was only in the 1980s that this developmental face of cancer was forgotten. The close connection between stem cells and cancer was recently rediscovered through the hopes invested in the use of human embryonic stem cells for regenerative medicine, but also through the difficulties encountered (Morange, 2006) . Human embryonic stem cells were shown to be oncogenic, as the mouse embryonic stem cells had been 20 years ago. Stem cells are a minor fraction of the cells present in the tumour, but are those responsible for tumour growth, exactly as embryonal carcinoma cells were shown to be the active population in teratocarcinomas 40 years ago.
Tumour growth as an evolutionary process
The role of somatic stem cells in the formation of tumours is still an open question, as are the complex relations between the existence and control of stem cells, the risk of cancer and the process of ageing. Nevertheless, this potential relation between cancer and stem cells also supports an evolutionary view of tumour growth. The idea of Darwinian competition between the body and the tumour is not new, and was argued at length by August Weismann at the end of the nineteenth century. What is more interesting and new is the subtle way in which the relation is now conceived in terms of strategies. A mutation is considered to give a growth advantage to the cancerous cell, but in a given environment, which has to be precisely described. In addition, any growth advantage has a certain cost. This cost can be a loss of adaptability of the cell, and this constitutes an Achilles' heel of the tumour targeted by the treatment. The relations between a tumour and the body that harbours it are now considered as the result of the formation of a favourable niche by the tumour. By niche construction, evolutionists designate the process by which organisms not only adapt to their environment, but also modify it. In this view, the relations between organisms and their environment are therefore re-equilibrated (Odling-Smee et al., 2003) . The niche construction model is particularly well adapted for explaining the way metastases form: recent studies have described some of the mechanisms by which tumour cells prepare, directly or indirectly, a 'pre-metastatic niche' (Kaplan et al., 2005; Hiratsuka et al., 2006) .
New therapeutic approaches
Such changes in the hypotheses concerning the origin and development of cancer could lead to dramatic shifts in the therapeutic approach to cancer. With the development of radiotherapy, and later chemotherapy, the dominant paradigm has been that the best way to eliminate tumours is to kill rapidly dividing cells. If the cells that cause tumours are stem cells, which are dormant most of the time, such efforts appear partially misplaced. It would be more efficient to induce the differentiation of these stem cells by adding differentiating factors (Piccirillo et al., 2006) .
The simple idea that, to fight cancer, it is sufficient to target the oncogene to which the tumour is 'addicted'
The field of cancer research M Morange will have also to be tempered. It does not mean that these specific drugs will be abandoned, but less specific drugs could prevent the appearance of the phenomenon of resistance. As Frantz (2005) said, 'Playing dirty becomes the rule'. The costs induced by any potentially oncogenic mutation could be exploited if they were better known: the unexpected specificity (against cancer) of drugs that inhibit essential parts of the cellular machinery might be explained in this way. Anothernot incompatible -interpretation is that the transformed cell is on the verge of instability, and a mild -for a normal cell -treatment could tip it into a catastrophic state. The paradoxical success of the combination of anti-angiogenic therapy and traditional chemotherapeutic agents (Kerbel, 2006) , paradoxical since the former treatment ought to reduce the efficiency of the latter, is probably explained by the complex relations between the tumour and its environment, that is, by the specific characteristics of the niche constructed by the tumour. The evidence that the stromal cells play a major role in the development of tumours (Bissell and Radisky, 2001) , and the more recent demonstration that these cells might mutate at one or other step of the complex process of tumour formation and growth (Pelham et al., 2006) , once again underline the complexity of the relation between the tumour and the body, of the 'cancer niche', and also point to new ways of fighting tumours.
Conclusions
The importance of a systemic vision of cancer is obvious: simple characterization of mutations is insufficient; what has to be understood is the new functional state reached by the tumour cell. For that, the study of the transcriptome is more important than drawing up the list of mutations (Bild et al., 2006) . The notion of cause has to be reconsidered, and so sterile debates abandoned. If a cascade of events (mutations) is responsible for the formation of tumours, as was proposed, for instance, in colorectal cancer (Kinzler and Vogelstein, 1996) , it is possible to consider that the first event in the cascade, the trigger, is the cause of the resulting tumour. But if cancer corresponds to a new functional state, which can be reached by diverse pathways, corresponding to genetic or epigenetic events, triggered or not by the environment, the notion of cause becomes elusive, and the debate on the reductionist and holistic explanations of cancer (Soto and Sonnenschein, 2004) useless. These transformations of the hypotheses explaining cancer and its development, as well as trends in therapeutic approaches, underline changes that are presently common to all biology: cancer research and biological research always had close relations (Cairns, 1978) . Contrary to what is frequently said, molecular descriptions and explanations have not been abandoned. But they are no longer considered as sufficient. They do not cover all that has to be explained. They have to be complemented by explanations derived from evolutionary studies and the physical sciences. Researchers have to intertwine explanatory schemes that hitherto have been considered as distinct and sufficient in their own right: molecular, evolutionary and physical. The abandonment of the simple, mechanistic notion of cause constitutes a dramatic change in present-day biology, the impact of which is seen in other fields of biological research, such as evolutionary studies and epidemiology. Causes are multiple and different in nature, with no hierarchy between them.
